US2020062837A1PendingUtilityA1
Anti-ngf compositions and use thereof
Est. expiryDec 1, 2030(~4.4 yrs left)· nominal 20-yr term from priority
Inventors:Benjamin H. DutzarBrian R. KovacevichPatricia Dianne McneillDanielle M. MitchellEthan W. OjalaPei FanJens J. BillgrenErica StewartCorinne C. AkatsukaBetty Y. ChangJohn LathamLeon F. Garcia-Martinez
A61P 43/00A61P 37/08A61P 31/04A61P 25/04A61P 27/02A61P 25/06A61P 35/00A61P 29/00A61P 25/00A61P 21/00A61P 19/10A61P 19/02A61P 19/00A61P 17/00A61P 15/00A61P 1/18A61P 1/16C07K 16/2875C07K 2317/92C07K 2317/565C07K 2317/76A61K 45/06A61K 2039/505C07K 2317/94C07K 2317/24A61K 39/3955C07K 2317/622C07K 16/22A61K 51/1021C07K 2317/41C07K 2317/55A61P 1/00Y02A50/30
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.
Claims
exact text as granted — not AI-modified1 . An anti-human NGF antibody or antibody fragment which comprises the same CDR polypeptides as an anti-human NGF antibody selected from Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13, Ab14, Ab15, Ab16, Ab17, Ab18, Ab19, Ab20, and Ab21.
2 - 5 . (canceled)
6 . The anti-human NGF antibody or fragment according to claim 1 , wherein said fragment is a Fab fragment comprising a V H polypeptide at least 90% identical to one selected from those in SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, 133, 143, 153, 163, 173, 183, 193, or 402 and/or V L polypeptide sequence at least 90% identical to one selected from: SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 141, 151, 161, 171, 181, 191, or 401.
7 - 21 . (canceled)
22 . The anti-human NGF antibody or fragment of claim 1 , which is directly or indirectly attached to a detectable label or therapeutic agent.
23 . A nucleic acid sequence or nucleic acid sequences which result in the expression of an anti-human NGF antibody or antibody fragment according to claim 1 .
24 - 26 . (canceled)
27 . A recombinant cell which expresses an antibody or antibody fragment according to claim 1 .
28 - 31 . (canceled)
32 . A method of treatment comprising administering to a patient with a disease or condition associated with NGF expressing cells a therapeutically effective amount of at least one anti-human NGF antibody or fragment according to claim 1 .
33 . The method of claim 32 wherein the disease is selected from inflammatory pain, post-operative incision pain, complex regional pain syndrome, cancer pain, primary or metastatic bone cancer pain, fracture pain, osteoporotic fracture pain, pain resulting from burn, osteoporosis, gout joint pain, pain associated with sickle cell crises, and other nociceptic pain, as well as hepatocellular carcinoma, breast cancer, liver cirrhosis, neurogenic pain, neuropathic pain, nociceptic pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovarialgia, reflex sympathetic dystrophy, neurogenic pain, osteoarthritis or rheumatoid arthritis pain, lower back pain, diabetic neuropathy, sciatica, or migraine.
34 - 57 . (canceled)
58 . A method of making an antibody according to claim 1 , in a recombinant host cell or non-human transgenic animal or plant containing one or more heterologous polynucleotides encoding said antibody.
59 - 117 . (canceled)
118 . An anti-NGF antibody or antibody fragment according to claim 1 , comprising a variable light chain polypeptide sequence and a variable heavy chain polypeptide sequence selected from the following:
Variable Light
Variable Heavy
Chain
Chain
A
Seq ID No: 1
Seq ID No: 3
B
Seq ID No: 11
Seq ID No: 13
C
Seq ID No: 21
Seq ID No: 23
D
Seq ID No: 31
Seq ID No: 33
E
Seq ID No: 41
Seq ID No: 43
F
Seq ID No: 51
Seq ID No: 53
G
Seq ID No: 61
Seq ID No: 63
H
Seq ID No: 71
Seq ID No: 73
I
Seq ID No: 81
Seq ID No: 83
J
Seq ID No: 91
Seq ID No: 93
K
Seq ID No: 101
Seq ID No: 103
L
Seq ID No: 111
Seq ID No: 113
M
Seq ID No: 121
Seq ID No: 123
N
Seq ID No: 131
Seq ID No: 133
O
Seq ID No: 141
Seq ID No: 143
P
Seq ID No: 151
Seq ID No: 153
Q
Seq ID No: 161
Seq ID No: 163
R
Seq ID No: 171
Seq ID No: 173
S
Seq ID No: 181
Seq ID No: 183
T
Seq ID No: 191
Seq ID No: 193
119 . An anti-NGF antibody or antibody fragment according to claim 1 , comprising a light chain polypeptide sequence and a heavy chain polypeptide sequence selected from the following:
Light Chain
Heavy Chain
Ab1
Seq ID No: 2
Seq ID No: 4
Ab2
Seq ID No: 12
Seq ID No: 14
Ab3
Seq ID No: 22
Seq ID No: 24
Ab4
Seq ID No: 32
Seq ID No: 34
Ab5
Seq ID No: 42
Seq ID No: 44
Ab6
Seq ID No: 52
Seq ID No: 54
Ab7
Seq ID No: 62
Seq ID No: 64
Ab8
Seq ID No: 72
Seq ID No: 74
Ab9
Seq ID No: 82
Seq ID No: 84
Ab10
Seq ID No: 92
Seq ID No: 94
Ab11
Seq ID No: 102
Seq ID No: 104
Ab12
Seq ID No: 112
Seq ID No: 114
Ab13
Seq ID No: 122
Seq ID No: 124
Ab14
Seq ID No: 132
Seq ID No: 134
Ab15
Seq ID No: 142
Seq ID No: 144
Ab16
Seq ID No: 152
Seq ID No: 154
Ab17
Seq ID No: 162
Seq ID No: 164
Ab18
Seq ID No: 172
Seq ID No: 174
Ab19
Seq ID No: 182
Seq ID No: 184
Ab20
Seq ID No: 192
Seq ID No: 194
Ab21
Seq ID No: 401
Seq ID No: 402
120 - 144 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.